Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Robins/Rorer

Executive Summary

Next important date in the road to merger is Oct. 19. A hearing is scheduled in Richmond federal court on that day on Robins' motion for approval of a definitive merger plan. One hurdle was cleared on Oct. 1, with the encouragement of the court, when the Robins family execs worked out an agreement on indemnification with Rorer. The Robins execs reportedly had wanted the right to sell Rorer stock if necessary to pay for personal claims in the future. They settled for other protections in the agreement.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS012583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel